

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 September 2023 (14.09.2023)



(10) International Publication Number
WO 2023/170087 A1

(51) International Patent Classification:

A61K 48/00 (2006.01) C07K 14/54 (2006.01)
A61P 35/00 (2006.01) C07K 14/705 (2006.01)
C07K 14/47 (2006.01) C12N 15/113 (2010.01)
C07K 14/52 (2006.01) C12N 15/86 (2006.01)

(21) International Application Number:

PCT/EP2023/055785

(22) International Filing Date:

07 March 2023 (07.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22382208.1 07 March 2022 (07.03.2022) EP

(71) Applicant: INNATHER GENE THERAPY S. À R.L.
[LU/LU]; 17, Boulevard F.W. Raiffeisen, 2411 Luxembourg (LU).


(72) Inventors: PRIETO VALTUEÑA, Jesús María; c/o FUNDACION NAVARRA PARA LA ASISTENCIA MEDICA EN AFRICA; Avda. Pio XII 55, 31008 Pamplona (Navarra) (ES). MARCO MARTÍNEZ, Sonia; c/o FUNDACION PARA LA INVESTIGACION MEDICA APLICADA; Avda. Pio XII 55, 31008 Pamplona (Navarra) (ES). HONORATO Cía, Beatriz; c/o FUNDACION PARA LA INVESTIGACION MEDICA APLICADA; Avda. Pio XII 55, 31008 Pamplona (Navarra) (ES). TENESACA CAYAMBE, Shirley Mireya; c/o FUNDACION PARA LA INVESTIGACION MEDICA APLICADA; Avda. Pio XII 55, 31008 Pamplona (Navarra) (ES). GOULD, David James; 34 Graham Avenue; Ealing, London London W13 9TQ (GB).

(74) Agent: FARAGO PATENTANWÄLTE GMBH; Schloß-Rahe-Str. 15, 52072 Aachen (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: EXPRESSION SYSTEM FOR THE TREATMENT OF CANCER

Fig. 5



(57) Abstract: The invention relates to a recombinant expression system for the treatment of cancer based on the "Stimulator of interferon genes" (STING) and comprising two nucleic acid constructs. The invention further relates to an expression vector or a combination of two expression vectors encoding said nucleic acid construct(s) and to a viral particle or a combination of two viral particles comprising said expression vector(s). The invention also relates to a pharmaceutical composition that comprises said recombinant expression system, said expression vector(s) or said viral particle(s). The invention also relates to the use of said recombinant expression system, said expression vector(s), said viral particle(s) or said pharmaceutical composition for use in an immunotherapy, especially in the immunotherapy of a proliferative disorder like cancer. The invention finally relates to the administration of the expression vectors in combination with radiotherapy for the treatment of cancer.

[Continued on next page]

WO 2023/170087 A1

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))